Publications by authors named "Alvaro Pinto"

Claim this Profile
F
Fluorescence sensing mechanism of contaminant Cu in water by up-converting nanoparticles.
Rubén Puga, Gabriel López-Peña, Elisa Ortiz, Alvaro Pinto, Gino Troya

Spectrochim Acta A Mol Biomol Spectrosc· March 2026

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
ctDNA-Guided Adjuvant Atezolizumab in Muscle-Invasive Bladder Cancer.
Thomas Powles, Ariel G Kann, Daniel Castellano, Marine Gross-Goupil, Hiroyuki Nishiyama, Alvaro Pinto

N Engl J Med· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Systematic Review of the Definition of Cure and of Curative-intent Treatments in Early Bladder Cancer.
Félix Guerrero-Ramos, Carsten Schwenke, Álvaro Pinto, Siobhán Mulhern-Haughey, Marta Pisini

Eur Urol Oncol· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Real-world evidences on adjuvant Pembrolizumab for renal cell carcinoma: results from the multicenter real-world ARON-1 study.
Ray Manneh Kopp, Francesco Massari, Enrique Grande, Timothy J Schieber, Yüksel Ürün, Alvaro Pinto

Cancer Immunol Immunother· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Time to metastasis as a prognostic factor in metastatic urothelial carcinoma: results from the ARON-2 study.
Renate Pichler, Gerald Klinglmair, Kirstin Binz, Enrique Grande, Alina Pirshtuk, Alvaro Pinto

Clin Exp Metastasis· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cabozantinib in the First-Line Treatment of Patients With Metastatic Renal Cell Carcinoma, Real-World Data From the Czech Republic and Poland: ICARO-RC Project.
Jakub Kucharz, Alexandr Poprach, Bożena Sikora-Kupis, Marta Darewicz, Piotr Domański, Alvaro Pinto

Clin Genitourin Cancer· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The role of radium-223 in the evolving treatment landscape of metastatic castration-resistant prostate cancer: A narrative review.
Álvaro Pinto, Mario Domínguez, Alfonso Gómez-Iturriaga, Alejo Rodriguez-Vida, Juan Antonio Vallejo-Casas

Crit Rev Oncol Hematol· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Retrospective study assessing the role of the androgen receptor in clear cell renal cell cancer patients treated with VEGFR inhibitors in monotherapy.
Lucia Osorio, Tatiana P Grazioso, Guillermo de Velasco, Olatz Etxaniz, Jose Luis Pérez-Gracia, Álvaro Pinto

Clin Transl Oncol· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Real-world treatment patterns, survival outcomes, and health care resource utilization for locally advanced or metastatic urothelial carcinoma in Spain.
Javier Puente, Alvaro Pinto, Maria José Mendez-Vidal, Xavier García Del Muro, Pablo Maroto

Clin Transl Oncol· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pembrolizumab-axitinib versus nivolumab-cabozantinib as first-line therapy in patients with metastatic renal cell carcinoma: a retrospective real-world comparison (ARON-1).
Matteo Santoni, Giandomenico Roviello, Enrique Grande, Ugo De Giorgi, Ondrej Fiala, Alvaro Pinto

Cancer Immunol Immunother· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Lenvatinib plus Pembrolizumab Following Immune Checkpoint Inhibitor Treatment in Patients with Metastatic Clear Cell Renal Cell Carcinoma: Results from Study 111/KEYNOTE-146.
Chung-Han Lee, Amishi Yogesh Shah, Arpit Rao, Matthew H Taylor, Christopher Di Simone, Alvaro Pinto

Eur Urol· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Enfortumab Vedotin Following Platinum Chemotherapy and Avelumab Maintenance in Patients with Metastatic Urothelial Carcinoma: A Retrospective Data from the ARON-2 Study.
Ondřej Fiala, Francesco Massari, Umberto Basso, Patrizia Giannatempo, Enrique Grande, Alvaro Pinto

Target Oncol· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Radiotherapy plus pembrolizumab for advanced urothelial carcinoma: results from the ARON-2 real-world study.
Mimma Rizzo, Andrey Soares, Enrique Grande, Aristotelis Bamias, Ray Manneh Kopp, Alvaro Pinto

Sci Rep· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Potential role of transmembrane 9 superfamily member 1 as a biomarker in urothelial cancer.
Alvaro Pinto, Abrahams Ocanto, Felipe Couñago

World J Clin Oncol· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Real-World Impact of Upfront Cytoreductive Nephrectomy in Metastatic Non-Clear Cell Renal Cell Carcinoma Treated with First-Line Immunotherapy Combinations or Tyrosine Kinase Inhibitors (A Sub-Analysis from the ARON-1 Retrospective Study).
Ondřej Fiala, Sebastiano Buti, Aristotelis Bamias, Francesco Massari, Renate Pichler, Alvaro Pinto

Target Oncol· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Global real-world experiences with pembrolizumab in advanced urothelial carcinoma after platinum-based chemotherapy: the ARON-2 study.
Francesco Massari, Matteo Santoni, Hideki Takeshita, Yohei Okada, Jose Carlos Tapia, Alvaro Pinto

Cancer Immunol Immunother· April 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Review of Recent Advances in the Management of Alzheimer's Disease.
Skylynn Thangwaritorn, Christopher Lee, Elena Metchikoff, Vidushi Razdan, Suliman Ghafary, Alvaro Pinto

Cureus· April 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Case-control study assessing the impact of COVID19 in advanced kidney cancer patients treated with antiangiogenics or immunotherapy: the COVID-REN study.
Jesús García-Donas, Guillermo de Velasco, Rodrigo Madurga, Jesús Chamorro, Diana Rosero, Álvaro Pinto

Clin Transl Oncol· March 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Real-world Outcome of Patients with Advanced Renal Cell Carcinoma and Intermediate- or Poor-risk International Metastatic Renal Cell Carcinoma Database Consortium Criteria Treated by Immune-oncology Combinations: Differential Effectiveness by Risk Group?
Matteo Santoni, Sebastiano Buti, Zin W Myint, Marco Maruzzo, Roberto Iacovelli, Alvaro Pinto

Eur Urol Oncol· February 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Different outcomes among patients with intermediate-risk metastastic renal cell carcinoma treated with first-line tyrosine-kinase inhibitors.
Álvaro Pinto, Jesús Miranda, Ana Pertejo, Mario Álvarez-Maestro, Pilar González-Peramato

Clin Transl Oncol· February 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase II trial of afatinib in patients with advanced urothelial carcinoma with genetic alterations in ERBB1-3 (LUX-Bladder 1).
Albert Font, Begona Mellado, Miguel A Climent, Juan Antonio Virizuela, Stephane Oudard, Alvaro Pinto

Br J Cancer· February 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Use of concomitant proton pump inhibitors, statins or metformin in patients treated with pembrolizumab for metastatic urothelial carcinoma: data from the ARON-2 retrospective study.
Ondřej Fiala, Sebastiano Buti, Hideki Takeshita, Yohei Okada, Francesco Massari, Alvaro Pinto

Cancer Immunol Immunother· November 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinico-Pathological Features Influencing the Prognostic Role of Body Mass Index in Patients With Advanced Renal Cell Carcinoma Treated by Immuno-Oncology Combinations (ARON-1).
Matteo Santoni, Francesco Massari, Zin W Myint, Roberto Iacovelli, Martin Pichler, Alvaro Pinto

Clin Genitourin Cancer· October 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Geographical differences in the management of metastatic de novo renal cell carcinoma in the era of immune-combinations.
Camillo Porta, Aristotelis Bamias, Roubini Zakopoulou, Zin W Myint, Nicolò Cavasin, Alvaro Pinto

Minerva Urol Nephrol· August 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Global Real-World Outcomes of Patients Receiving Immuno-Oncology Combinations for Advanced Renal Cell Carcinoma: The ARON-1 Study.
Matteo Santoni, Francesco Massari, Zin W Myint, Roberto Iacovelli, Martin Pichler, Alvaro Pinto

Target Oncol· July 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis